After Endo, global plans for BDSI's Belbuca?
BioDelivery Sciences International announced Thursday that Endo Pharmaceuticals will terminate its licensing of rights for one of its buprenorphine products, Belbuca, thereby transferring those rights back to BDSI effective Jan. 6.
Additionally, Endo said Thursday it is eliminating its 375-member branded pain medicine sales forces in the United States in a move that will allow the company to focus its resources on other core products.
While BDSI CEO Mark Sirgo says the arrangement is not what the...